GeneDx Shareholders Face August 3 Deadline in Securities Class Action

The legal action, brought by the firm Levi & Korsinsky under the brand SueWallSt, alleges that GeneDx issued misleading statements regarding the integration and revenue potential of Fabric Genomics between April 16, 2025, and May 4, 2026. While management initially touted the software as a source of recurring revenue, the company ultimately revealed that the platform was suited only for international markets, far narrower than the broad clinical utility originally promised to investors.

The situation culminated on May 5, 2026, when GeneDx shares plummeted 49.20%, or $33.42 per share, following a $65 million reduction in full-year revenue guidance. The complaint highlights a series of disclosures where management’s optimism—including claims of a 74% adjusted gross margin—clashed with subsequent reports of declining reimbursement rates and missed targets. Joseph E. Levi, the attorney representing the firm, noted that the timeline of these developments raises significant questions regarding the discrepancy between internal knowledge and public communication. Investors who purchased WGS stock during the class period may be eligible for recovery regardless of whether they still hold the shares.